Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review.

Simone Rossi, Elena Merli, Rita Rinaldi, Gaia Deleonardi, Vincenzo Mastrangelo, Anna Simona Sasdelli, Alessandro Di Federico, Maria Guarino, Vincenzo Donadio, Loris Pironi, Francesco Gelsomino, Roberto De Giorgio, Roberto D'Angelo

Journal: Journal of neurology 2022;269(3):1182-1194

PMID: 33934212

Abstract

OBJECTIVES

This work aimed to report the demographic and clinical characteristics of two new cases with non-paraneoplastic anti-Hu-associated gut motility impairment, and perform a thorough revision covering anti-Hu-associated paraneoplastic (PGID) and non-paraneoplastic (nPGID) gastrointestinal dysmotility.

BACKGROUND

Several case series have clearly established a relationship between certain type of cancers, the development of circulating anti-Hu antibodies, and the concomitant usually severe gastrointestinal dysmotility; in contrast, a few studies focused on anti-Hu-associated nPGID.

METHODS

We searched for studies regarding anti-Hu-associated gastrointestinal manifestations and extracted data concerning clinical characteristics of patients, including specific demographic, oncological, neurological, gastrointestinal, histological, and treatment response features.

RESULTS

Forty-nine articles with a total of 59 cases of anti-Hu-associated gastrointestinal dysmotility were analyzed. The patients' age at symptom onset significantly differed between PGID and nPGID (median 61 vs 31 years, p < 0.001). Most cancers (95%) in PGID were detected within 24 months from the beginning of gastrointestinal symptoms. The impairment of gastrointestinal motility was generalized (i.e., involving the whole gut) in 59.3% of patients, with no significant differences between PGID vs nPGID group. nPGID patients showed a better response to immunomodulatory/immunosuppressive treatment and a longer life expectancy.

CONCLUSIONS

Anti-Hu-associated gastrointestinal dysmotility covers a wide clinical spectrum. Patients with otherwise unexplained gastrointestinal dysmotility, especially when associated with other neurological symptoms, should be tested for anti-Hu antibodies regardless age of onset and disease duration. Compared to PGID, nPGID occurs in younger patients with a long duration of disease.

© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Address: IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.; Metropolitan Laboratory, Department of Immunology, AUSL Bologna, Bologna, Italy.; Clinical Nutrition and Metabolism Unit-Centre for Chronic Intestinal Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Bologna, Italy.; Department of Translational Medicine, University of Ferrara, Ferrara, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. [email protected].

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.